ISSN 1941-5923



American Journal of Case Reports have been selected for the ESCI - Emerging Sources Citation Index (Thomson Reuters, Web of Science, ISI), launching in November of 2015 as a new edition of the Web of Science.

Clinical... read more

Published: 2016-08-24

Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report

Leon Louis Seifert, Hauke Heinzow, Iyad Kabar, Stefan Christensen, Anna Hüsing, Hartmut H.-J. Schmidt

(Department of Transplantation Medicine, University Hospital Münster, Münster, Germany)

Am J Case Rep 2016; 17:605-610

DOI: 10.12659/AJCR.895839

BACKGROUND: Direct-acting antivirals (DAAs) represent a new hallmark in antiviral therapy of hepatitis C virus (HCV). DAAs have been shown to be safe and effective after liver transplantation (LT), but there is little information about their use in peritransplant settings. Former intravenous drug users represent an increasing group seeking HCV treatment. This case report demonstrates the successful peritransplant antiviral treatment of a former intravenous drug user who had been treated in a methadone maintenance program.
CASE REPORT: The patient was diagnosed with Child B cirrhosis for the first time in 2009. He had a Model for End-stage Liver Disease (MELD) score of 21 and started antiviral therapy with sofosbuvir (SOF) and daclatasvir (DCV) in March 2014. Due to hepatic decompensation, he received a LT in April 2014. Immunosuppression was performed with tacrolimus (TAC) and mycophenolate-mofetil (MMF), and boosted with prednisolone in the initial stage. Four weeks after his LT, the patient presented with an acute renal injury. The patient was discharged one week later after sufficient hydration, discontinuation of non-steroidal anti-phlogistics therapy, and adjustments to his immunosuppressive regimen. At the beginning of his therapy, the number of RNA copies was 13,000 IU/mL. He received 24 weeks of anti-HCV treatment with SOF and DCV; the antiviral treatment was successful and his LT was well tolerated. 
CONCLUSIONS: Treatment of HCV is feasible in a peritransplant setting. The antiviral regimen we used did not seem to have any relevant interactions with the patient’s immunosuppressive regimens. Still, the peritransplant setting is a very dema... read more

Keywords: Antiviral Agents, drug users, Hepatitis C, Liver Transplantation

Published: 2016-08-22

Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: ...

Tomohide Hori, Yasuharu Onishi, Hideya Kamei, Nobuhiko Kurata, Masatoshi Ishigami, Yoji Ishizu, Yasuhiro Ogura

Am J Case Rep 2016; 17:597-604

DOI: 10.12659/AJCR.898427

Published: 2016-08-19

Concurrent Nontuberculous Mycobacteria Infection and High-Grade Anterior Mediastinal Extraskeletal Osteos...

Gabriel T. Faz, Mahmoud Eltorky, Bernard Karnath

Am J Case Rep 2016; 17:592-596

DOI: 10.12659/AJCR.898730